RESUMO
As highly tissue-specific genes, it is increasingly recognized that long non-coding RNAs (lncRNAs) are considered as promising prognostic biomarkers for multiple human cancers. However, lack of tissue-specific lncRNAs in gastric cancer (GC) still exist. In this study, we identified a novel lncRNA LINC01939 which showed the largest fold change in GC than other human cancers from lnCAR database by bioinformatic analysis. Reverse transcription quantitative polymerase chain reaction (qPCR) assay confirmed that LINC01939 was significantly downregulated in GC tissues compared with matched normal tissues. Low expression of LINC01939 was positively associated with advanced TNM stage and lymphatic metastasis. Patients with low LINC01939 expression have remarkably shorter overall survival (OS) and progression-free survival (PFS) than those with high LINC01939 expression. Univariate and multivariate analysis showed that LINC01939 is an independent protective predictor of OS and PFS in GC patients. Therefore, our data suggest that the newly identified lncRNA LINC01939 might act as a potential prognostic biomarker for GC.
Assuntos
RNA Longo não Codificante/genética , Neoplasias Gástricas/patologia , Adulto , Idoso , Biomarcadores Tumorais/genética , Progressão da Doença , Intervalo Livre de Doença , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Prognóstico , Neoplasias Gástricas/genética , Neoplasias Gástricas/mortalidadeRESUMO
OBJECTIVE: To study the outcome of pregnancy with systemic lupus erythematosus (SLE) treated by DNA immunoabsorbent therapy. METHODS: Sixty nine SLE women with pregnancy were randomly enrolled into DNA immunoabsorbent group (35, group I) and common therapeutic group (34, group II) as control. Outcomes of pregnancy and complications were analyzed. RESULTS: The incidence of complication and fetus loss in group I was 28.6% (10 cases) and 20.0% (7 cases), while 85.3% (29 cases) and 58.8% (20 cases) in group II, there was very significant difference respectively (P < 0.01). The incidence of premature birth was 8.6% (3 cases) in group I, 26.5% (9 cases) in group II, the difference was significant (P < 0.05). CONCLUSION: DNA immunoabsorbent was more efficient than common therapy in the management of SLE with pregnancy.
Assuntos
DNA/uso terapêutico , Imunoadsorventes/uso terapêutico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Complicações na Gravidez/tratamento farmacológico , Adulto , Feminino , Feto , Humanos , Hidrocortisona/uso terapêutico , Trabalho de Parto Prematuro/prevenção & controle , GravidezRESUMO
In order to investigate the therapeutic effects of Lishengsu, a domestic preparation of recombinant human granulocyte colony stimulating factor, the recovery of leukopenia was observed in 58 patients with malignant tumors after chemotherapy. In these patients, 7 cases were in first cycle of chemotherapy and 51 were given in repeated cycles. When blood leukocyte level decreased to less than 3x10(9)/L, Lishengsu was subcutaneously injected for 3-5 days at a dose of 75 microgram or 150 microgram per day. The results showed that Lishengsu remarkably alleviated the degree of leukopenis and accelerated the leukocyte counts recovered to normal level. The promotive effects of Lishengsu to recovery of leukopenia were dependent on degree of leukopenia at start of administration of Lishengsu. The curative effect of Lishengsu to chemotherapy-induced leukopenia was reliable with slight side-effects